Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

 Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI™

ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers

Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI

Transaction is expected to close in the summer of 2025

https://finance.yahoo.com/news/ligand-subsidiary-pelthos-therapeutics-combine-100000828.html